EAM Global Investors LLC Acquires Shares of 108,564 Exelixis, Inc. (NASDAQ:EXEL)

EAM Global Investors LLC bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 108,564 shares of the biotechnology company's stock, valued at approximately $3,615,000.

A number of other hedge funds have also added to or reduced their stakes in the business. USA Financial Formulas acquired a new position in shares of Exelixis during the fourth quarter valued at about $32,000. Principal Securities Inc. raised its holdings in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after buying an additional 373 shares during the last quarter. Kestra Investment Management LLC bought a new position in shares of Exelixis during the fourth quarter valued at about $39,000. UMB Bank n.a. boosted its holdings in Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 553 shares during the last quarter. Finally, Crowley Wealth Management Inc. bought a new position in shares of Exelixis during the 4th quarter worth approximately $50,000. 85.27% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Morgan Stanley raised Exelixis from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $30.00 to $40.00 in a research report on Monday, January 27th. StockNews.com upgraded Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 19th. Wells Fargo & Company reiterated a "market outperform" rating on shares of Exelixis in a research report on Thursday. Barclays raised their price objective on Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Finally, Oppenheimer cut shares of Exelixis from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the transaction, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. This trade represents a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock worth $5,177,234 in the last 90 days. Insiders own 2.85% of the company's stock.

Exelixis Stock Performance

Shares of EXEL traded down $0.17 during trading hours on Monday, hitting $36.02. 505,288 shares of the stock were exchanged, compared to its average volume of 2,168,907. The stock's 50-day moving average price is $36.44 and its two-hundred day moving average price is $34.36. The company has a market cap of $10.08 billion, a price-to-earnings ratio of 20.35, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.